With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Headline: The PDGFRɑ-inhibitor olaratumab failed to improve survival among the 509 patients with unresectable and/or metastatic soft tissue sarcoma enrolled on the phase 3 ANNOUNCE trial. In fact, median progression-free survival was significantly worse with olaratumab (5 months) versus placebo (7 months). TBL: As feared, the PDGFRɑ-inhibitor olaratumab isn’t the long awaited savior for soft-tissue sarcoma. | Tap, ASCO 2019